The impact of the new WHO antiretroviral treatment Guidelines on HIV epidemic dynamics and cost in South Africa
Background Since November 2009, WHO recommends that adults infected with HIV should initiate antiretroviral therapy (ART) at CD4+ cell counts of ≤350 cells/µl rather than ≤200 cells/µl. South Africa decided to adopt this strategy for pregnant and TB co-infected patients only. We estimated the impact...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 20, 2011
|
| In: |
PLOS ONE
Year: 2011, Volume: 6, Issue: 7, Pages: e21919 |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0021919 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1371/journal.pone.0021919 Verlag, Volltext: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021919 
|
| Author Notes: | Jan A. C. Hontelez, Sake J. de Vlas, Frank Tanser, Roel Bakker, Till Bärnighausen, Marie-Louise Newell, Rob Baltussen, Mark N. Lurie |
| Summary: | Background Since November 2009, WHO recommends that adults infected with HIV should initiate antiretroviral therapy (ART) at CD4+ cell counts of ≤350 cells/µl rather than ≤200 cells/µl. South Africa decided to adopt this strategy for pregnant and TB co-infected patients only. We estimated the impact of fully adopting the new WHO guidelines on HIV epidemic dynamics and associated costs. Methods and Finding We used an established model of the transmission and control of HIV in specified sexual networks and healthcare settings. We quantified the model to represent Hlabisa subdistrict, KwaZulu-Natal, South Africa. We predicted the HIV epidemic dynamics, number on ART and program costs under the new guidelines relative to treating patients at ≤200 cells/µl for the next 30 years. During the first five years, the new WHO treatment guidelines require about 7% extra annual investments, whereas 28% more patients receive treatment. Furthermore, there will be a more profound impact on HIV incidence, leading to relatively less annual costs after seven years. The resulting cumulative net costs reach a break-even point after on average 16 years. Conclusions Our study strengthens the WHO recommendation of starting ART at ≤350 cells/µl for all HIV-infected patients. Apart from the benefits associated with many life-years saved, a modest frontloading appears to lead to net savings within a limited time-horizon. This finding is robust to alternative assumptions and foreseeable changes in ART prices and effectiveness. Therefore, South Africa should aim at rapidly expanding its healthcare infrastructure to fully embrace the new WHO guidelines. |
|---|---|
| Item Description: | Gesehen am 05.10.2017 |
| Physical Description: | Online Resource |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0021919 |